Suppr超能文献

城市人群中出现新生血管性年龄相关性黄斑变性患者的患病率。

Prevalence of patients presenting with neovascular age-related macular degeneration in an urban population.

作者信息

Zawinka Claudia, Ergun Erdem, Stur Michael

机构信息

Department of Ophthalmology, University of Basel, Basel, Switzerland.

出版信息

Retina. 2005 Apr-May;25(3):324-31. doi: 10.1097/00006982-200504000-00012.

Abstract

PURPOSE

To determine the number and type of new cases of neovascular age-related macular degeneration (AMD) present in a defined urban population and to establish the proportion that would be recommended for treatment with verteporfin or laser photocoagulation.

METHODS

Patients referred to an ophthalmic center in Vienna during a 10-week period because of recent deterioration in vision caused by newly diagnosed neovascular AMD were included.

RESULTS

Neovascular AMD was diagnosed in 168 eyes in 153 patients. One hundred one eyes (60.1%) had lesions that were occult with no classic choroidal neovascularization (CNV); of these, 70 were subfoveal, 19 were juxtafoveal, and 12 were extrafoveal. Thirty-five eyes (20.8%) had predominantly classic lesions; of these, 27 were subfoveal, 6 were juxtafoveal, and 2 were extrafoveal. Thirty-two eyes (19.0%) had minimally classic lesions, of which 31 were subfoveal and 1 was extrafoveal. In accordance with consensus guidelines from a panel of experts and with American Academy of Ophthalmology's Preferred Practice Pattern guidelines, 33 lesions (17%) would be considered for treatment with verteporfin therapy. A further 37 subfoveal lesions with occult with no classic CNV and 7 juxtafoveal lesions with occult with no classic CNV might also benefit from verteporfin therapy if there is evidence of presumed recent disease progression. Five lesions (3.0%) could have been treated with laser photocoagulation according to Macular Photocoagulation Study criteria.

CONCLUSIONS

These results suggest that verteporfin therapy substantially increases the number of patients with treatable neovascular AMD.

摘要

目的

确定特定城市人群中新生血管性年龄相关性黄斑变性(AMD)新发病例的数量和类型,并确定推荐使用维替泊芬或激光光凝治疗的比例。

方法

纳入在10周内因新诊断的新生血管性AMD导致视力近期下降而转诊至维也纳眼科中心的患者。

结果

153例患者的168只眼中诊断为新生血管性AMD。101只眼(60.1%)有隐匿性病变,无典型脉络膜新生血管(CNV);其中,70只为黄斑中心凹下,19只为黄斑中心凹旁,12只为黄斑中心凹外。35只眼(20.8%)主要为典型病变;其中,27只为黄斑中心凹下,6只为黄斑中心凹旁,2只为黄斑中心凹外。32只眼(19.0%)有微小典型病变,其中31只为黄斑中心凹下,1只为黄斑中心凹外。根据专家小组的共识指南和美国眼科学会的首选实践模式指南,33个病变(17%)将被考虑采用维替泊芬治疗。如果有证据表明疾病近期进展,另外37个隐匿性无典型CNV的黄斑中心凹下病变和7个隐匿性无典型CNV的黄斑中心凹旁病变也可能从维替泊芬治疗中获益。根据黄斑光凝研究标准,5个病变(3.0%)可用激光光凝治疗。

结论

这些结果表明,维替泊芬治疗显著增加了可治疗的新生血管性AMD患者数量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验